Emily Bodnar’s ranking is based over the anticipation of considerable milestones for Agenus in the approaching calendar year, specifically the opportunity filing of a Biologics License Application (BLA) for their lead drug candidate, botensilimab (bot). Agenus has dosed in excess of 900 people with bot throughout numerous stable tumors, demonstra